Randomized controlled trials support the fact that anti-VEGF agents and DEX implants may be used as a first-line therapy for macular edema secondary to RVO.10,11,12 In addition, laser photocoagulation can contribute by reducing the number of intravitreal injections in appropriate cases. This evidence concerns the gene VEGFA and macular retinal edema.